Skip to main
TNDM

TNDM Stock Forecast & Price Target

TNDM Analyst Ratings

Based on 16 analyst ratings
Hold
Strong Buy 6%
Buy 25%
Hold 69%
Sell 0%
Strong Sell 0%

Bulls say

Tandem Diabetes Care has demonstrated promising financial performance, achieving revenue estimates of $1.111 million for 2026 and $1.229 million for 2027, slightly above prior expectations. The company is expected to return to positive new patient start growth in the U.S. by 2026, driven by increasing adoption of the innovative Mobi pump and improved access through pharmacy channels. Notably, Tandem realized a revenue beat of approximately $14 million, primarily attributed to strong U.S. market performance and successful pricing strategies linked to pharmacy penetration.

Bears say

Tandem Diabetes Care has experienced substantial operating losses since its inception, raising concerns about its ability to achieve sustained profitability. Projections indicate a potential decline in new patient starts within the U.S. diabetes pump market, coupled with risks from competitive pressures and challenges in securing favorable pharmacy channel contracts, which may hinder the company's growth. Despite exceeding shipment estimates, a year-over-year decrease in U.S. pump shipments and lower profit margins compared to its peers further contribute to the negative outlook on the company's financial health.

TNDM has been analyzed by 16 analysts, with a consensus rating of Hold. 6% of analysts recommend a Strong Buy, 25% recommend Buy, 69% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Tandem Diabetes Care and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Tandem Diabetes Care (TNDM) Forecast

Analysts have given TNDM a Hold based on their latest research and market trends.

According to 16 analysts, TNDM has a Hold consensus rating as of Feb 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $23.62, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $23.62, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Tandem Diabetes Care (TNDM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.